Here are the 10-K annual reports from SWK Holdings Corporation 9.00% Senior Notes due 2027 (SWKHL) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SWKHL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SWKHL filings page.
SWK Holdings Corporation files its Annual Report outlining a specialty finance strategy focused on healthcare and life sciences. The company’s business now centers on its Finance Receivables segment after selling substantially all assets of its Pharmaceutical Development segment in 2025.
SWK provides royalty-backed and revenue interest financings, mainly in sub-$50 million transactions, and has funded about $876.1 million across 58 parties as of March 7, 2026. As of June 30, 2025, common equity held by non-affiliates was valued at $45,770,456, and 12,095,979 common shares were outstanding as of March 16, 2026.
The report highlights extensive risk factors, including credit losses on royalty and debt investments, heavy regulation of life sciences, dependence on third parties to market royalty-generating products, limited portfolio diversification, cybersecurity and AI-related risks, significant influence from a controlling stockholder group, and potential impacts from announced mergers.